Nurix Therapeutics to Participate in Upcoming Investor Conference
BRISBANE, Calif., April 07, 2026 -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today announced that Arthur Sands, M.D., Ph.D., president and chief executive officer of Nurix, will participate in a fireside chat at the 25
- Needham Virtual Healthcare Conference
Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix
Monday, April 13, 2026, at 1:30 – 2:10 p.m. ET
The fireside chat will be webcast live and may be viewed via a link in the Investors section of the Nurix website. The archived webcast will be available for 30 days after the event.
About Nurix Therapeutics, Inc.
Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and autoimmune diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of a preclinical stage degrader of STAT6 in collaboration with Sanofi, a clinical stage degrader of IRAK4 in collaboration with Gilead, as well as additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by an AI-integrated discovery engine capable of tackling virtually any protein class, and coupled with unparalleled ligase expertise, Nurix has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit.
Contacts:
Investors
Kris Fortner
Nurix Therapeutics, Inc.
Kris Fortner
Nurix Therapeutics, Inc.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nifty 50 Is Still Down 4.91% in 2026, So Why Does Citi See 13% Upside?
US Dollar Index: Fed path and CPI focus – Deutsche Bank
VIPMidterm Elections Conclude, Anthropic Initiates IPO
1. Cross-asset performance diverged this week. Between the October 30 and November 6 closes, the S&P 500 fell 2.68%, the Nasdaq 100 dropped 4.91%, and BTC lost 1.88%. Gold and silver rose 4.51% and 5.79%, respectively, while the Hang Seng gained 5.10%. Sharp declines in crude oil and some Asian equity indexes showed how differently assets responded to growth, policy, and event risks. 2. Democrats won majorities in both chambers of Congress in the US midterm elections, and markets rallied before reversing. We focus on actual changes in fiscal negotiations, key committee arrangements, and local industrial policy, especially data-center approvals, energy costs, and the pace of capital expenditure. We do not map party outcomes directly to asset direction. 3. The pullback in technology stocks has put returns on AI investment under renewed scrutiny. Whether rapid growth can cover financing, construction, and ongoing compute costs is becoming a key valuation test. For related positions, monitor policy implementation, customer capital expenditure, and cash collection together, and do not read a one-day rebound as a sign that the pressure has passed. 4. Anthropic's IPO preparations are putting the growth quality, operating profitability, and funding needs of AI model companies under public-market scrutiny. Valuations discussed for the offering are not final pricing, and participating in related products also requires assessing fees, allocation methods, asset rights, and trading restrictions. Assets in focus: BTC, the Nasdaq 100, crude oil, and gold, along with key earnings from companies including CSCO, AMAT, and CEG
Asian Stocks Rebound, Nikkei Up 3.4%, but Can They Lead Wall Street?
Crypto prices
More
